I am working on designing immunomodulatory antibody therapies, including T-cell agonists, T-cell engagers, and immunocytokines. These molecules have shown promise for treating a number of diseases, including cancer and autoimmunity.

Co-advised by Prof. Peter Tessier

Exploration of Krogh cylinder model refinement with payload recycling.

The recent successes of ADCs in the clinic have underscored the importance of tailoring ADC drug properties for specific targets. However, the complexity of these molecules poses a challenge in thoroughly screening all potential combinations of protein, linker, and payload during development. My work focuses on applying fundamental drug transport principles to efficiently design ADCs for maximum efficacy at clinically tolerated doses.

Modeling drug uptake and distribution across the BBB (Blood-Brain Barrier) to enable the testing of hypotheses for applications such as treating neurodegenerative diseases (e.g., Alzheimer’s and MS) and cancer. 

Co-advised by Prof. Peter Tessier

I will be working on developing specialized ADCs with Fc-engineered domain to maximize immune response and drive lasting tumor remission.